- AuthorisedTherapeutic exploratory (Phase II)
Phase II Prospective Multicenter Study of High-Dose Treosulfan/Melphalan as Consolidation Treatment in Newly Diagnosed High-Risk and Very High-Risk Ewing Sarcoma.
This study is looking at a new, stronger chemotherapy treatment for people with high-risk Ewing Sarcoma. It combines medicines like Treosulfan and Melphalan to see how safe and effective they are. The aim is to find better ways to stop this cancer from coming back.
For: Ewing SarcomaItaly - RecruitingPHASE3
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
This study looks at new ways to treat high-risk neuroblastoma, a type of cancer, in children and young people. Researchers are testing different combinations of chemotherapy and radiation to find the most effective treatments to help patients live longer and healthier lives.
For: High-Risk Neuroblastoma · Patient With Insufficient Response ChemoimmunotherapyAustralia · Austria · Belgium - Ongoing, recruitingTherapeutic exploratory (Phase II)
ABCSG 45: A prospective, open, randomized, phase II study of carboplatin/olaparib in the pre-operative treatment of patients with triple-negative primary breast cancer which exhibit the features of positive homologous recombination deficiency (HRD) status
This study looks at a new combination treatment for a specific type of early breast cancer. It compares giving a drug called olaparib with carboplatin before surgery, with a standard chemotherapy. The aim is to see if the new treatment shrinks the cancer more effectively.
For: Early invasive triple negative breast cancer with positive HRD status (acc. to Myriad mychoice© test)Austria - Active not recruitingPHASE3
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)
This study compares a new drug combination (Lurbinectedin and Doxorubicin) against Doxorubicin alone for people with advanced leiomyosarcoma, a rare type of cancer. It aims to see if the combination can keep the cancer from growing for longer.
For: LeiomyosarcomaUnited States · Austria · Belgium - RecruitingPHASE2
A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome
This study is testing a new drug, acalabrutinib, alongside the usual treatment (CHOP-R) for Richter's Syndrome. It aims to see if this combination improves outcomes for people recently diagnosed with this aggressive blood cancer.
For: Richter SyndromeUnited Kingdom - Active not recruitingPHASE3
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
This study looks at a new drug, sacituzumab govitecan, for women with endometrial cancer that has come back or hasn't responded to earlier treatments. It compares this new drug to standard treatments chosen by doctors, aiming to see if it helps women live longer or keeps cancer from growing.
For: Endometrial CancerUnited States · Australia · Brazil - RecruitingPHASE2
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)
This study looks at new treatments (Dostarlimab alone or with Bevacizumab) for certain gynaecological cancers that have come back or not responded to previous treatment, comparing them to standard chemotherapy. It aims to see which treatment works best.
For: Ovarian Neoplasms · Endometrial Neoplasms · Uterine Cervical NeoplasmsAustralia · Hong Kong · Japan - RecruitingPHASE2
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
This study compares two treatments for a fast-growing blood cancer called diffuse large B-cell lymphoma (DLBCL), specifically a type called GCB DLBCL. Researchers want to see if a new drug, zilovertamab vedotin, when combined with standard therapy, works better than another combination in shrinking the cancer.
For: Lymphoma, Large B-Cell, DiffuseUnited States · Belgium · Germany - Active not recruitingPHASE3
Paediatric Hepatic International Tumour Trial
This study, called PHITT, is for children and young people up to 30 years old with liver cancers called hepatoblastoma (HB) and hepatocellular carcinoma (HCC). It aims to find better ways to treat these cancers by using tailored treatments and studying them closely.
For: Hepatoblastoma · Carcinoma, HepatocellularAustria · Belgium · Czechia - Active not recruitingPHASE3
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
This study compares a new treatment, axicabtagene ciloleucel, with standard care for adults recently diagnosed with high-risk large B-cell lymphoma. It aims to see if the new treatment works better as a first treatment option.
For: High-risk Large B-cell Lymphoma (LBCL)United States · Australia · Austria - Active not recruitingPHASE2
A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
This study looks at a new drug, golcadomide, combined with standard treatment for follicular lymphoma that's been recently diagnosed and is advanced. We want to see how well this new combination works and if it's safe for patients.
For: Lymphoma, FollicularUnited States · Australia · Brazil - Active not recruitingPHASE3
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
This study is looking at new ways to treat a type of breast cancer that doesn't have certain hormone receptors or HER2 protein, called triple-negative or hormone receptor-low/HER2-negative breast cancer. It tests two different treatment plans using new and existing medicines before and after surgery.
For: Breast CancerUnited States · Australia · Austria - RecruitingPHASE3
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
This study is for people with early-stage Hodgkin Lymphoma. It compares two chemotherapy treatments, ABVD and A2VD, to see which works best. Treatment is adjusted based on scans, and patients are followed for at least 5 years.
For: Hodgkin LymphomaUnited States · Australia · Belgium - Active not recruitingPHASE3
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
This study is looking at a new treatment combination for a type of blood cancer called Diffuse Large B-cell Lymphoma (DLBCL). It combines a new drug, tafasitamab, and another drug, lenalidomide, with standard chemotherapy to see if it works better than chemotherapy alone.
For: Diffuse Large B-cell LymphomaUnited States · Argentina · Australia - RecruitingPHASE3
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
This study compares a new drug, odronextamab, with standard treatment for a type of lymphoma called DLBCL. It looks at how well they work with chemotherapy and their safety in adults who haven't been treated before, or whose lymphoma has come back.
For: Diffuse Large B-cell Lymphoma (DLBCL)United States · Australia · Austria - RecruitingPHASE3
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
This study compares a new drug, Puxitatug Samrotecan, with standard chemotherapy for advanced endometrial cancer that has returned after previous treatments. It aims to see if the new drug can help patients live longer or stop their cancer from getting worse.
For: Endometrial Cancer · Malignant Solid TumourUnited States · Argentina · Australia - Active not recruitingPHASE3
Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma
This study is looking at a new treatment called axicabtagene ciloleucel for follicular lymphoma that has come back or hasn't responded to other treatments. It compares this new treatment to standard care to see how well it works.
For: Relapsed/Refractory Follicular LymphomaUnited States · France · Germany - Active not recruitingPHASE3
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
This study is looking at a new treatment called glofitamab for a type of cancer called large B-cell lymphoma. It compares this new treatment, along with other medicines, against a standard treatment for people who haven't had treatment before.
For: Large B-Cell LymphomaUnited States · Argentina · Australia - RecruitingPHASE3
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
This study looks for better ways to treat early-stage, high-risk breast cancer. It tests a new targeted therapy, sacituzumab tirumotecan, with other standard treatments to see if it reduces cancer and helps people live longer without the cancer returning.
For: Breast Neoplasms · Triple Negative Breast Neoplasms · HR Low-Positive/HER2-Negative Breast NeoplasmsUnited States · Argentina · Australia - AuthorisedTherapeutic confirmatory (Phase III)
OPTIMA YOUNG : Optimal Personalized Treatment of early breast cancer using Multi-parameter Analysis : focus on YOUNGer women
This study, OPTIMA YOUNG, is for younger women with a common type of early breast cancer. It looks at the best way to treat this cancer to stop it from coming back, by comparing different medications and how well they work.
Poland · France · Italy - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA 25) – Substudy B – Relapsed/Refractory Richter Transformation (RT)
This study looks at a new cell therapy called Tecartus for adults with a type of blood cancer called Richter Transformation that has come back or not responded to previous treatments. It aims to see how well it works and if it's safe.
For: Relapsed/refractory Richter Transformation (RT)France · Germany · Spain - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA 25) – Substudy C – Relapsed/Refractory Burkitt Lymphoma (BL)
This study is looking at a new treatment called Tecartus for adults in the UK with a specific type of blood cancer called Burkitt Lymphoma. It's for patients whose cancer has come back or hasn't responded to previous treatments. Researchers want to see how well Tecartus works.
For: Relapsed/Refractory Burkitt Lymphoma (BL)Netherlands · France · Austria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)
This study looks at a new way to treat an aggressive type of breast cancer called Triple Negative Breast Cancer (TNBC). It combines a special immune-boosting drug (Pembrolizumab) with standard chemotherapy to see if it can shrink tumours more effectively before surgery and prevent them from returning.
For: Triple Negative Breast Cancer (TNBC)Portugal · Germany · Poland - Ongoing, recruitingTherapeutic exploratory (Phase II)
Phase 2 Study of Pembrolizumab and Chemotherapy in Patients With Newly Diagnosed Classical Hodgkin Lymphoma (KEYNOTE-C11)
This study looks at a new treatment called pembrolizumab, combined with standard chemotherapy, for adults recently diagnosed with classical Hodgkin lymphoma. Researchers want to see how many patients go into complete remission at the end of the treatment plan.
For: Classical Hodgkin LymphomaFrance · Poland · Spain - AuthorisedTherapeutic exploratory (Phase II)
A Phase II Open Label Study of Brentuximab Vedotin in Combination with CHEP in Patients with Previously Untreated CD30-expressing Peripheral T-cell Lymphomas (PTCL)
This study is looking at a new combination of medicines, including Brentuximab Vedotin (Adcetris), for adults with a type of cancer called CD30-expressing Peripheral T-cell Lymphoma (PTCL) that hasn't been treated before. We want to see how well this new treatment shrinks the cancer.
For: CancerCzechia - Ongoing, recruitingTherapeutic exploratory (Phase II)
A prospective multicenter phase 2 study of copanlisib in combination with rituximab and CHOP chemotherapy (COPA-R-CHOP) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL)
This study looks at a new drug, BAY 80-6946, with standard chemotherapy for a type of blood cancer called diffuse large B-cell lymphoma (DLBCL). It's in an early stage (Phase 2), focusing on finding the best dose and checking if the treatment is safe and effective.
For: Diffuse large B-cell lymphoma (DLBCL)Germany - Active not recruitingPHASE3
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
This study compares a new medicine, sacituzumab tirumotecan, with standard chemotherapy for endometrial cancer. It's for people whose cancer has returned or progressed after previous treatments (platinum-based chemotherapy and immunotherapy). Researchers want to see if the new medicine helps people live longer and keeps the cancer from getting worse.
For: Endometrial CancerUnited States · Argentina · Australia - RecruitingPHASE3
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
This study is testing a new drug, odronextamab, for adults with follicular lymphoma that hasn't been treated before. It aims to find out if the drug is safe and how well it works compared to current standard treatments.
For: Follicular Lymphoma (FL)United States · Australia · Austria - Active not recruitingPHASE2
Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)
This study looks at a new drug, pembrolizumab, combined with standard chemotherapy for children and young adults (3-25 years old) with newly diagnosed classical Hodgkin Lymphoma. It specifically focuses on those who aren't responding quickly to initial treatment.
For: Hodgkin LymphomaUnited States · Brazil · Colombia - RecruitingPHASE1, PHASE2
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
This study is testing a new drug, surovatamig, for different types of B-cell blood cancers like leukaemia and lymphoma. Researchers want to see if it's safe and effective, either alone or with other cancer treatments.
For: Chronic Lymphocytic Leukaemia · Small Lymphocytic Lymphoma · Mantle-cell LymphomaUnited States · Australia · China - RecruitingPHASE3
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
This study is looking at a new drug, epcoritamab, combined with standard treatments for follicular lymphoma, a type of blood cancer. We want to see if this combination is safe and effective in people who haven't been treated for this condition before.
For: Follicular Lymphoma (FL)United States · Australia · Belgium - Active not recruitingPHASE3
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
This study is looking into a new drug, epcoritamab, for people with a type of blood cancer called Diffuse Large B-cell Lymphoma (DLBCL). It compares epcoritamab combined with standard treatment (R-CHOP) to R-CHOP alone, to see if the new combination works better.
For: Diffuse Large B-Cell LymphomaUnited States · Australia · Austria - Active not recruitingPHASE2
Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC
This study is looking into a new treatment for an aggressive type of breast cancer called triple-negative breast cancer. It combines standard chemotherapy with two newer drugs, Atezolizumab and Ipatasertib, to see if this mix can fight the cancer better before surgery.
For: Triple Negative Breast CancerUnited Kingdom - RecruitingPHASE3
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
This study looks at a new drug, golcadomide, combined with rituximab, for people with follicular lymphoma that has come back or not responded to previous treatments. It compares this new combination to standard treatments chosen by doctors.
For: Follicular LymphomaUnited States · Australia · Brazil - RecruitingPHASE1, PHASE2
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
This study, FaR-RMS, is for children and adults with a type of cancer called rhabdomyosarcoma. It's looking for better ways to treat both newly diagnosed and returning cancer, using different combinations of medicines and radiotherapy.
For: RhabdomyosarcomaAustralia · Austria · Belgium - RecruitingPHASE3
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
This study is looking at a new treatment (BNT323) for women with advanced womb cancer that has come back. It compares BNT323 to standard chemotherapy to see if it works better at shrinking tumours and keeping the cancer from growing.
For: Endometrial CancerUnited States · Argentina · Australia - AuthorisedTherapeutic exploratory (Phase II)
PROSPECTIVE, PHASE II STUDY TO EVALUATE THE EFFICACY OF ADDITION OF PROGESTERONE TO STANDARD CHEMOTHERAPY ACCORDING TO EDP SCHEME PLUS MITOTANE IN PATIENTS WITH ADVANCED ADRENAL CORTICAL CARCINOMA - PESETA TRIAL
This study is looking at new ways to treat advanced adrenal cancer. It's comparing standard chemotherapy with a combination that includes progesterone and another drug called mitotane, to see if the new combination works better at shrinking tumours.
For: Adrenocortical carcinomaItaly - Active not recruitingPHASE3
A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma
This study is testing a new drug called odronextamab with chemotherapy for follicular lymphoma. It compares this new combination to the usual treatment (rituximab with chemotherapy) to see if it's safe, works well, and helps people with this type of cancer.
For: Follicular Lymphoma (FL)United States · Australia · Austria - RecruitingPHASE3
High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)
This study looks at new ways to treat a serious childhood cancer called neuroblastoma. It tests different treatment combinations, including chemotherapy and immunotherapy, to find the best approach for children with high-risk forms of the disease. The aim is to improve their chances of getting better.
For: NeuroblastomaAustralia · Austria · Belgium - RecruitingPHASE2
Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy
The REFRACT trial explores new treatments for follicular lymphoma that has come back or not responded to previous therapy. It compares new drugs with standard care to see if they offer better results for patients.
For: Relapsed Follicular Lymphoma · Refractory Follicular LymphomaUnited Kingdom